Alzheimer's disease

Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab. The Analysts Mizuho Securities analyst Salim Syed...

Undeterred by the failure of one of its Alzheimer's pipeline assets, Eisai Co., Ltd (OTC: ESALY) is stepping up efforts to further advance its clinical pipeline.  Apart from aducanumab — for which trials were scrapped — the company has two more assets for Alzheimer...

Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer's drug study. What Happened Biogen and its partner Japan-based Eisai said they will discontinue an ongoing global Phase 3...

Biotechs Axsome Therapeutics Inc (NASDAQ: AXSM) and Axovant Sciences Ltd (NASDAQ: AXON) were taking diverging paths Monday.  While shares of Axsome surged higher by nearly 8 percent, Axovant shares were down by more than 25 percent at the time of publication.  Positive Interim Results...

Biogen Inc (NASDAQ: BIIB) shares, which ended Tuesday's session at a three-year high following a beat-and-raise second-quarter report, are experiencing continued momentum after a poster presentation on the company's Alzheimer's disease candidate co-developed with Japan's...

Neurotrope Inc (NASDAQ: NTRP) announced Monday that it has initiated enrollment for a confirmatory Phase 2 study of bryostatin-1 in Alzheimer’s disease. The typically good news of a drug candidate's progress may not be enough to clear the public's memory of Neurotrope. The stock...

While AC Immune SA (NASDAQ: ACIU)’s crenezumab Alzheimer's treatment could be a breakthrough if trials prove successful, the faraway approval and launch timelines for the drug could mean the stock will see few catalysts over the next 12 months, according to Credit Suisse. The Analyst...

"Age is just a number, not a state of mind or a reason for any type of particular behavior." -Cecelia Ahern Alzheimer's disease is the sixth leading cause of death in the U.S., although recent estimates indicate it may now be the third most common cause of death, behind heart disease...

Pain Therapeutics, Inc. (NASDAQ: PTIE) shares took center stage Monday, offering pleasure rather than pain to those investing in the company. The shares of the clinical-stage biopharma company gap-opened up at $4.20, adding over 12 percent from the previous session's close of $3.74....

Corium International (NASDAQ: CORI) shares have been white hot over the past 10 days, rising more than 30 percent since the company reported positive preliminary results in the clinical study of its Corplex Donepezil Alzheimer's Disease (AD) product candidate. The Data In a pilot...

Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...

Neurotrope Inc (OTC: NTRP), a clinical stage biopharmaceutical company, may have found through its drug Bryostatin a unique solution to addressing Alzheimer's, one of the last major diseases with no cure. Benzinga recently spoke with CEO Dr. Susanne Wilke, ahead of her appearance at the...

Shares of AC Immune Ltd (NASDAQ: ACIU), a medical biotechnology company that focuses on the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases, soared higher by more than 23 percent after the company's partner Genentech published an editorial. AC Immune and Genentech have...

Shares of Biogen Inc (NASDAQ: BIIB) were trading up almost 1.2 percent on Thursday afternoon shortly before the closing bell. The movement apparently comes on the back of updated and embargoed aducanumab titration data leaked from the 9th Clinical Trials on Alzheimer's Disease (CTAD) congress...

Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...